Aratana Therapeutics
Aratana Therapeutics, Inc. is a company dedicated to the development and commercialization of therapeutics for dogs and cats in the United States. The firm offers a range of products, including NOCITA, a post-operative analgesic for dogs, ENTYCE for appetite stimulation, and GALLIPRANT for managing pain and inflammation related to osteoarthritis in dogs. It is also advancing various therapeutic candidates such as a bupivacaine liposome injectable suspension for cats, a formulation of capromorelin for cats, and an oral CRTH2 antagonist for treating atopic dermatitis in dogs. Additionally, Aratana is exploring treatments for feline herpes virus-related conditions and canine lymphoma, among others. The company collaborates with Elanco Animal Health, Pacira Pharmaceuticals, and AskAt Inc. to enhance its product development and commercialization efforts. Founded in 2010 and headquartered in Leawood, Kansas, Aratana Therapeutics operates as a subsidiary of Elanco Animal Health Incorporated.
Okapi Sciences NV, a Belgium-based company with a proprietary pet therapeutics antiviral platform and five clinical/development stage candidates for treating important viral diseases. The strategic acquisition of Okapi further enhances Aratana's leadership position in pet therapeutics by bringing with it a unique combination of individuals, strong relationships with academic institutions, novel technologies and products, and favorable geographic location. Aratana plans to continue to advance the current Okapi pipeline of high value antiviral drugs, including its feline herpes and feline immunodeficiency virus franchises.
Vet Therapeutics is developing antibody-based therapies to treat pet cancer and chronic conditions. The company is committed to bringing the same modality of products that constitute the standard of care in humans to animal health by applying world-class science to new products for companion animals. The Vet Therapeutics team has more than 30 years' experience and a successful track record at developing antibody-based biologics for humans, which is directed towards the development of pet-specific biologics to treat pet cancer and chronic conditions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.